Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Oncology

Life After Treatment: Monitoring and Kidney Health

At a Glance

After treatment for clear cell renal carcinoma (ccRCC), survivorship focuses on monitoring for recurrence with regular CT scans and protecting your remaining kidney. Managing blood pressure, controlling blood sugar, and avoiding NSAIDs are critical for preserving kidney function.

After treatment for ccRCC, you enter the survivorship phase. This period is focused on two main goals: monitoring for any sign that the cancer has returned and protecting your remaining kidney function. While the “all clear” from surgery is a relief, living with the uncertainty of potential recurrence is a significant emotional challenge that requires a proactive plan [1][2].

Your Surveillance Roadmap

Monitoring schedules are not “one size fits all.” Your doctors (following AUA or NCCN guidelines) will tailor your scans based on your individual risk level—determined by your tumor’s stage and grade [3][4].

  • Low Risk (e.g., small T1 tumors): You may only need a baseline scan within the first 6–12 months, followed by annual imaging for at least 5 years [5].
  • Intermediate to High Risk: Scans are more frequent, often occurring every 3–6 months for the first two years, then every 6–12 months for several years after [3][6].

Doctors primarily use CT scans of the chest, abdomen, and pelvis to check the lungs, liver, kidney bed, and lymph nodes [7]. While ccRCC can spread to the bones, standard CT scans don’t cover the entire skeleton. If you experience new, persistent bone pain, a dedicated bone scan or targeted MRI will be ordered [8][9].

Protecting Your “Golden” Kidney

Whether you have one full kidney or part of one left, protecting your remaining “filters” (nephrons) is vital. Individuals with a solitary kidney are at a higher risk for Chronic Kidney Disease (CKD) [10].

  • Watch Your Blood Pressure: High blood pressure is a leading cause of kidney damage. Managing it through diet (specifically low salt intake) and medication is essential [11][12].
  • Manage Diabetes: If you have diabetes, strict blood sugar control is the best way to prevent further strain on your kidney [12].
  • Avoid “Kidney-Toxic” Drugs: Be very cautious with NSAIDs (like ibuprofen or naproxen), which can reduce blood flow to the kidney. Always check with your doctor before taking new over-the-counter medications [12].

Managing “Scanxiety”

The anxiety that builds before a follow-up scan—often called scanxiety—is a real and intense experience for many survivors [13][14].

  • Preparation: When preparing for CT scans with contrast, staying well-hydrated and ensuring your kidney function (eGFR/creatinine) is checked beforehand is important, especially if you have a solitary kidney.
  • Focus on the Present: Strategies such as mindfulness or focusing on daily tasks can help pull your mind away from “what-if” future scenarios [15].
  • Advocate for Results: Ask your team how long results typically take and if they can be delivered via a phone call or patient portal as soon as they are ready to minimize the “waiting room” stress [16][13].

Symptoms to Watch For

While most recurrences are found on scheduled scans before they cause symptoms, you should contact your doctor if you notice [17]:

  • New, persistent bone pain.
  • A cough that doesn’t go away.
  • Unexplained weight loss or extreme fatigue.
  • New lumps in the abdomen or side.

Remember, surveillance is a safety net designed to catch issues early when they are most treatable. Being proactive about your kidney health and your emotional well-being is a key part of your recovery [1].

Common questions in this guide

How often will I need scans after ccRCC treatment?
Your scan schedule depends on your risk of recurrence. Low-risk patients may need a baseline scan within the first 6 to 12 months and then annually, while higher-risk patients often have scans every 3 to 6 months for the first two years.
What symptoms could mean my kidney cancer has returned?
Contact your doctor if you experience new and persistent bone pain, a cough that will not go away, unexplained weight loss, extreme fatigue, or new lumps in your abdomen or side.
How can I protect my remaining kidney function after cancer surgery?
You can protect your remaining kidney tissue by strictly managing your blood pressure and blood sugar levels. You should also avoid kidney-toxic medications like ibuprofen and naproxen unless approved by your doctor.
What tests are used to check for ccRCC recurrence?
Doctors primarily use CT scans of the chest, abdomen, and pelvis to monitor for recurrence. If you develop new bone pain, a dedicated bone scan or targeted MRI may be ordered to check the skeleton.
How can I cope with scanxiety before my follow-up appointments?
Preparing physically by staying well-hydrated before contrast scans can give you peace of mind. To manage mental stress, practice mindfulness, focus on daily tasks, and ask your medical team in advance how and when your results will be delivered.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my tumor's stage and grade, am I considered low, intermediate, or high risk for recurrence?
  2. 2.Can you provide a specific calendar of my scheduled CT or MRI scans for the next two years?
  3. 3.What is my current eGFR (kidney function score), and how often should it be checked?
  4. 4.Are there specific medications I must avoid now that I have a solitary (or partial) kidney?
  5. 5.How quickly will I receive my scan results, and who is the best person to contact if I’m feeling overwhelmed while waiting?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (17)
  1. 1

    Breast cancer survivorship.

    Valente S, Roesch E

    Journal of surgical oncology 2024; (130(1)):8-15 doi:10.1002/jso.27627.

    PMID: 38534002
  2. 2

    Gastric Cancer Survivorship: Multidisciplinary Management, Best Practices and Opportunities.

    Cobani E, Al Hallak MN, Shields AF, et al.

    Journal of gastrointestinal cancer 2024; (55(2)):519-533 doi:10.1007/s12029-023-01001-7.

    PMID: 38180678
  3. 3

    Mayo Clinic Validation of the AUA Risk Groups for Localized Renal Cell Carcinoma.

    Zganjar A, Khanna A, Joyce D, et al.

    The Journal of urology 2024; (212(2)):331-341 doi:10.1097/JU.0000000000004030.

    PMID: 38813884
  4. 4

    Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

    Motzer RJ, Jonasch E, Agarwal N, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2022; (20(1)):71-90 doi:10.6004/jnccn.2022.0001.

    PMID: 34991070
  5. 5

    Follow-up after curative treatment of localised renal cell carcinoma.

    Dabestani S, Marconi L, Kuusk T, Bex A

    World journal of urology 2018; (36(12)):1953-1959 doi:10.1007/s00345-018-2338-z.

    PMID: 29767327
  6. 6

    Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma.

    Yang Y, Psutka SP, Parikh AB, et al.

    Cancer medicine 2022; (11(16)):3106-3114 doi:10.1002/cam4.4679.

    PMID: 35304832
  7. 7

    Cross-sectional imaging assessment of renal masses with emphasis on MRI.

    Tsili AC, Moulopoulos LA, Varakarakis IM, Argyropoulou MI

    Acta radiologica (Stockholm, Sweden : 1987) 2022; (63(11)):1570-1587 doi:10.1177/02841851211052999.

    PMID: 34709096
  8. 8

    The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.

    Abu-Ghanem Y, Powles T, Capitanio U, et al.

    European urology oncology 2021; (4(3)):473-482 doi:10.1016/j.euo.2020.09.005.

    PMID: 33109495
  9. 9

    Determining the Impact of Histology on the Incidence, Pattern, and Timing of Recurrences in Patients with Renal Cell Carcinoma: A Pooled Analysis from the SORCE and ASSURE Trials.

    Oza B, Frangou E, Eisen T, et al.

    European urology open science 2025; (79()):19-26 doi:10.1016/j.euros.2025.07.003.

    PMID: 40756159
  10. 10

    Solitary kidney and risk of chronic kidney disease.

    Kim S, Chang Y, Lee YR, et al.

    European journal of epidemiology 2019; (34(9)):879-888 doi:10.1007/s10654-019-00520-7.

    PMID: 31025238
  11. 11

    Do children with solitary or hypofunctioning kidney have the same prevalence for masked hypertension?

    Yel S, Günay N, Pınarbaşı AS, et al.

    Pediatric nephrology (Berlin, Germany) 2021; (36(7)):1833-1841 doi:10.1007/s00467-020-04896-7.

    PMID: 33459937
  12. 12

    Pregnancy in women known to be living with a single kidney.

    Steele SE, Terry JE, Page LM, Girling JC

    Obstetric medicine 2019; (12(1)):22-26 doi:10.1177/1753495X18784081.

    PMID: 30891088
  13. 13

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  14. 14

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  15. 15

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  16. 16

    Scanxiety and quality of life around follow-up imaging in patients with unruptured intracranial aneurysms: a prospective cohort study.

    Kamphuis MJ, van der Kamp LT, van Eijk RPA, et al.

    European radiology 2024; (34(9)):6018-6025 doi:10.1007/s00330-024-10602-0.

    PMID: 38311702
  17. 17

    ACR Appropriateness Criteria® Post-Treatment Follow-up and Active Surveillance of Clinically Localized Renal Cell Carcinoma: 2021 Update.

    , Purysko AS, Nikolaidis P, et al.

    Journal of the American College of Radiology : JACR 2022; (19(5S)):S156-S174 doi:10.1016/j.jacr.2022.02.015.

    PMID: 35550799

This page provides general information about survivorship and life after ccRCC treatment. Always consult your oncology and nephrology teams for personalized surveillance plans and kidney care advice.

Get notified when new evidence is published on Clear cell renal carcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.